Re: All time low price in Hobbs/Kandarpa regime
okay, you "fully expect" a lot of positives for dcth in the near term... i've been here for 2-3 years and most here have always been very positive for all things dcth... huge potential/totally undervalued... today's pps is a great buying op... yada, yada, yada.
but last week, the market was valuing dcth at 2.50/sh... it was pricing lotsa risk in its valuation for this "$1B potential" drug.
now this week, dcth prices a measly $20M secondary at $1.50/sh... that smacks of desperation.
biotech's raise capital when they can... not when they need it.
could this capital raise be a tell that dcth is very concerned that the fda is gonna require a new trial(s) with the gen2 filter to refile the nda ?
nah, if that was the case, Hobbs shoulda/woulda stated that possibility, right ?... then again, maybe he did when they announced this secondary.